Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Total Current Assets : $0.13 Mil (As of Dec. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Eucrates Biomedical Acquisition's total current assets for the quarter that ended in Dec. 2022 was $0.13 Mil.

Eucrates Biomedical Acquisition Total Current Assets Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Total Current Assets Chart

Eucrates Biomedical Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Total Current Assets

1.02

0.26

0.13

Eucrates Biomedical Acquisition Quarterly Data
	Aug20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Total Current Assets	Get a 7-Day Free Trial					0.26	0.36	0.22	0.10	0.13

Eucrates Biomedical Acquisition Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Eucrates Biomedical Acquisition's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.019	+	0	+	0	+	0.113
	=	0.13

Eucrates Biomedical Acquisition's Total Current Assets for the quarter that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.019	+	0	+	0	+	0.113
	=	0.13

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Eucrates Biomedical Acquisition (NAS:EUCRU) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Eucrates Biomedical Acquisition's Liquidation Value for the quarter that ended in Dec. 2022 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.019	-	3.95	+	0.75 * 0	+	0.5 * 0
=	-3.93

Eucrates Biomedical Acquisition Total Current Assets Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

250 West 55th Street, Suite 13D, New York, NY, USA, 10019

Website

Eucrates Biomedical Acquisition Corp is a blank check company.

Executives

Stelios Papadopoulos	director, 10 percent owner	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell	director	270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro	director	2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena	director, 10 percent owner, officer: Chief Executive Officer	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal	officer: Vice President	250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova	officer: Chief Financial Officer	250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe	officer: Senior Vice President	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis	director, officer: President, COO	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal	director	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023